Sanofi-Aventis has notified the TGA that the tablet form of its vigabatrin product, Sabril, is in shortage The Therapeutic Goods Administration has said in a statement that the shortage has been triggered by a global recall. It is expected to last until 30 September 2023. The oral 500 mg powder sachet form of the product
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.